Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration

Hemodialysis International

Volumn 15, Issue 3, 2011, Pages 359-365

  Sivalingam, Murugan ^a   Suresh, Mathavakkannan ^a   Farrington, Ken ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

BNP; Cardiovascular disease; Hemodialysis; NT proBNP; Survival

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN; UREA;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HIGH FLUX HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; SURVIVAL TIME;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FOLLOW-UP STUDIES; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 79959969170     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00557.x     Document Type: Article

References (30)

1. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem. 2004; 50:33-50.
2. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339:321-328.
3. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995; 96:1280-1287.
4. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther. 1999; 289:976-980.
5. Alehagen U, Lindstedt G, Levin LA, Dahlstrom U. Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol. 2005; 100:125-133.
6. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev. 2003; 8:355-358.
7. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005; 46:610-620.
8. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004; 164:1978-1984.
9. Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001; 59:1559-1566.
10. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007; 50:2357-2368.
11. Hall C. The value of natriuretic peptides for the management of heart failure: Current state of play. Eur J Heart Fail. 2001; 3:395-397.
12. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108:2154-2169.
13. Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The posthemodialysis rebound: Predicting and quantifying its effect on Kt/V. Kidney Int. 1996; 50:2094-2102.
14. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009; 24:2502-2510.
15. Pencina MJ, D'Agostino RBS, D'Agostino RBJ, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27:157-172; discussion 207-12.
16. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal probrain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005; 293:1609-1616.
17. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003; 24:1735-1743.
18. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002; 106:2913-2918.
19. Olsen MH, Wachtell K, Tuxen C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study. J Hypertens. 2004; 22:1597-1604.
20. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004; 50:1071-1074.
21. Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christensen JH. NT-pro- BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol. 2009; 71:380-386.
22. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007; 71:548-554.
23. Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001; 12:1508-1515.
24. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007; 50:1009-1019.
25. Paniagua R, Ventura MD, Avila-Diaz M, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant. 2010; 25:551-557.
26. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V. Change in N-terminalpro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J. 2008; 29:2092-2099.
27. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3:1644-1651.
28. Sun L, Sun Y, Zhao X, et al. Predictive role of BNP and NT-proBNP in hemodialysis patients. Nephron Clin Pract. 2008; 110:c178-c184.
29. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Intern Med J. 2009; 39:812-818.
30. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysisdependent chronic renal failure. Clin Chim Acta. 2010; 411:936-939.